Moxonidine: A Second‐generation Central Antihypertensive Agent

Cardiovascular Drug Reviews

Volumn 11, Issue 4, 1993, Pages 411-431

  Ernsberger, Paul ^a   Elliott, Henry L ^b   Weimann, Hans‐Josef ^c   Raap, Achim ^d   Haxhiu, Musa A ^a   Hofferber, Eva ^a   Löw‐Kröger, Andrea ^d   Reid, John L ^b   Mest, Hans‐Jürgen ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTERN INFIRMARY   (United Kingdom)

^c Kali Chemie Pharma GmbH   (Germany)

^d NONE   (Germany)

Author keywords

Antihypertensive drugs; Central activity; Hypertension; Imidazoline receptors; Moxonidine

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; CAPTOPRIL; CLONIDINE; CYCLIC AMP; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLIBENCLAMIDE; GUANABENZ; GUANFACINE; HISTAMINE H2 RECEPTOR; HYDROCHLOROTHIAZIDE; IMIDAZOLINE RECEPTOR; LOFEXIDINE; METHYLDOPA; MOXONIDINE; NIFEDIPINE; PHENTOLAMINE; RILMENIDINE;

ADRENERGIC SYSTEM; AREA UNDER THE CURVE; BINDING AFFINITY; BLOOD PRESSURE; BRADYCARDIA; CHROMAFFIN CELL; CLINICAL TRIAL; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; EDEMA; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY MEDULLA; LOCUS CERULEUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SOLITARY TRACT NUCLEUS; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPATHETIC TONE; THALAMUS VENTRAL NUCLEUS; XEROSTOMIA;

EID: 0027850365     PISSN: 08975957     EISSN: 15273466     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1993.tb00198.x     Document Type: Article

References (133)

1. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats
2. Clonidine hypotension: lack of effect of bilateral lesions of the nucleus solitary tract in anaesthetized cats
3. Comparison of the effects of clonidine, guanfacine and BDF 5895 on plasma renin activity and arterial blood pressure in rats
4. 2‐adrenoceptors
5. 2‐adrenoceptor stimulation to the antihypertensive action of moxonidine
6. 2‐receptor selectivity and specificity of the antihypertensive agent moxonidine
7. General pharmacology of the novel centrally acting antihypertensive agent moxonidine
8. BE 5895, a new clonidine‐type antihypertensive aminopyrimidine derivative
9. Effect of temperature on alpha‐2‐ and alpha‐1‐adrenoceptor mediated responses in (he pithed rat and in the rat vena cava
10. 2‐adrenoceptors
11. + transport and intracellular pH in renal proximal tubule cells
12. 2‐adrenoceptor stimulation
13. Blockade of the central hypotensive effect of clonidine by alpha‐adrenoreceptor antagonists in rats, rabbits and dogs
14. Central cardiovascular effects of alpha‐adrenergic drugs: differences between catecholamines and imidazolines
15. 2‐adrenoceptors and “imidazoline receptors.”
16. Localization of the central cardiovascular action of clonidine
17. Alpha‐Adrenergic drugs: pharmacological tools for the study of the central nervous system
18. The imidazoline preferring receptor: Binding studies in bovine, rat and human brainstem
19. 2‐Adrenoceptor subtypes and imidazoline‐like binding sites in the rat brain.
20. 2‐adrenoceptors: Pharmacological and molecular biological evidsence converge
21. Alpha‐2A and alpha‐2B adrenergic receptor subtypes: Attenuation of cyclic AMP production in cell lines containing only one receptor subtype.
22. 2‐adrenergic receptors
23. Blood pressure, stroke and coronary heart disease, Part 2
24. Imidazoline‐guanidinium receptive site in renal proximal tubule: Asymetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance
25. Evidence for imidazoline binding sites in basolateral membranes from rabbit kidney
26. 2‐adrenoceptors affect sleep and arousal mechanisms
27. Effects of pertussis toxin on the behavioural and ECoG spectrum changes inducted by clonidine and yohimbine after their microinfusion into the locus coeruleus
28. Sympathetic neural control of the kidney in hypertension
29. Smooth muscle of rabbit aorta contains alpha‐1 but not alpha‐2 adrenoceptors
30. Demonstration of hypertrophy: regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine
31. Presynaptic receptor systems on the noradrenergic neurones of the rabbit pulmonary artery
32. 1‐imidazoline sites
33. Adrenal chromaffin cells express clonidine‐specific imidazole receptors which bind an endogenous clonidine‐displacing substance
34. Characterization and visualization of clonidine‐sensitive imidazole sites in rat kidney which recognize clonidine‐displacing substance
35. 2‐adrenergic receptors in the rostral ventrolateral medulla
36. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla
37. 1‐imidazoline receptor binding sites
38. 1‐imidazoline receptors and brainstem autonomic control: Membrane binding, autoradiographic and functional studies
39. Astrocytes cultured from specific brain regions differ in their expression of adrenergic binding sites
40. 125I‐PIC): possible chemosensory role
41. 2‐adrenoceptors in the ventrolateral medulla
42. 3H‐para‐aminoclonidine
43. An endogenous substance with clonidine‐like properties: selective binding to imidazole sites in the ventrolateral medulla
44. Neuroblastoma‐glioma hybrid cells contain clonidine‐displacing substance
45. 1‐imidazoline sites in rat renal medulla: Binding properties and up‐regulation by subpressor angiotensin infusion
46. 1‐adrenoceptors by nucleotides and metal ions
47. 1‐imidazoline receptors
48. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit
49. Do primary dysfunctions in neural control of arterial pressure contribute to hypertension
50. 2‐adrenoceptors in rat brain membranes
51. 2 receptor antagonists in the rat
52. A method of stimulating different segments of the autonomic outflow from the spinal column to various organs in the pithed cat and rat
53. Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area
54. The effect of clonidine on centrally and peripherally evoked submaxillary salivation
55. 2‐adrenoceptors
56. 1‐imidazoline agonist moxonidine administered into the rostral ventrolateral medulla (RVLM)
57. 1‐imidazoline agonist moxonidine administered into the rostral ventrolateral medulla
58. 1‐imidazoline agonist moxonidine is a selective antihypertensive: Lack of depressant action on central respiratory drive
59. Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats: A micromorphometric study
60. Maintenance of tonic vasomotor activity by alpha and beta adrenergic mechanisms in medullary cardiovascular centers
61. Brain and the regulation of blood pressure: a hemodynamic perspective
62. Role of sympathoadrenal medullary activation in the initiation and progression of atherosclerosis
63. Interrelationships between clonidine and histaminergic mechanisms
64. 2‐receptor involvement in the hypotensive effect of clonidine in the rat
65. 2‐receptors in the hypotensive effect of clonidine
66. 3H]idazoxan sites
67. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients
68. The influence of renal function on clinical pharmacokinetis of moxonidine
69. Central alpha‐adrenergic systems as targets for hypotensive drugs
70. 2‐adrenergic receptors in the carotid body response to isocapnic hypoxia
71. Interaction of clonidine and rilmenidine with imidazoline‐preferring receptors
72. 2‐adrenergic receptor. Identification of a unique receptor subtype
73. The imidazoline‐preferring receptor
74. Sympathetic activity: Modulator of myocardial hypertrophy
75. 2‐receptor classification
76. Moxonidin versus Captopril bei Patienten mit leichter bis mittelschwerer Hypertonie–Doppelblindstudie zur Wirksamkeit und Verträglichkeit
77. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats (SHR)—Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium
78. Effects of neuropeptide Y on forskolin, alpha sub(2)‐ and beta‐adrenoceptor‐regulated cAMP levels in the rat brain slice
79. Effect of some sulfonylurea derivatives in experimental ulcer formation in the rat
80. 2‐receptors in guinea‐pig isolated atria
81. 2+ in human erythroleukemia cells
82. 2‐adrenergic drugs also bind with high affinity to a nonadrenergic site.
83. Keep an eye on the I site: Imidazoline‐preferring receptors
84. Are there multiple imidazoline binding sites
85. 2‐adrenoceptors to imidazoline receptors: putative progress for cardiovascular therapy
86. Chemical stimulation of the locus coeruleus: Inhibitory effects on hemodynamics and renal sympathetic nerve activity
87. 2‐adrenergic blocker
88. Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide
89. Nonadrenergic modulation by clonidine of the cosecretion of catecholamines and enkephalins in adrenal chromaffin cells
90. Moxonidine effects on intraocular pressure and pupil diameter and contraction of the cat nictitating membrane
91. Moxonidine: A second generation of centrally acting drugs
92. Lack of pharmacokinetic interactions between moxonidine and digoxin
93. Non‐adrenergic imidazoline binding sites on human platelets
94. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension
95. Long‐term experience with moxonidine in arterial hypertension
96. Comparison of moxonidine and clonidine HCl in treating patients with hypertension
97. Pharmacokinetic‐pharmacodynamic modeling of the effect of clonidine on pain threshold, blood pressure, and salivary flow
98. 2‐adrenoceptors do not regulate catecholamine secretion by bovine adrenal medullary cells: A study with clonidine
99. Ventrolateral medullary pressor area: site of hypotensive action of clonidine
100. A double‐blind comparison of moxonidine and atenolol in the management of patients with mild‐to‐moderate hypertension
101. 1A and α‐adrenoceptors agonist in anaesthetized cats
102. Effects of clonidine and other imidazole‐receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells
103. Sympathetic neural and α‐adrenergic modulation of arrhythmias
104. Determination of moxonidine (BDF 5895) in plasma by gas chromatography‐negative ion chemical ionization mass spectrometry
105. 2autoreceptors are involved in the blood pressure‐lowering effect of moxonidine
106. Hypertension: A possible risk in road traffic
107. Antihypertensive Wirkdauer und morgendlicher Blutdruckanstieg unter Moxonidin in der ambulanten 24‐Stunden‐Blutdruckmessung
108. Langzeiterfahrungen mit Moxonidin, einem neuen Antihypertensivum
109. A pithed rat preparation suitable for assaying pressor substance
110. 2 adrenoceptors
111. 2‐adrenergic receptors in nucleus tractus solitarius is required for the baroreceptor reflex
112. Absolute bioavailability of moxonidine
113. Influence of food on the oral bioavailability of moxonidine
114. Age‐related effects on the pharmacokinetics of moxonidine
115. An imidazoline‐specific mechanism for the hypotensive effect of clonidine: A study with yohimbine and idazoxan
116. Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline‐preferring receptors
117. Characterization of alpha‐adrenergic receptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine, and corynanthine
118. Alpha‐adrenoceptors: classification, localization, mechanisms, and targets for drugs
119. A new method for investigating the isometric contractile responses of small blood vessels
120. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers
121. Further investigations on the interaction between α‐adrenoceptor antagonists and the central hypotensive effect of clonidine in rats, rabbits and dogs
122. Haemodynamic effects of a new centrally acting antihypertensive agent moxonidine as compared to clonidine
123. 2A‐selective compound
124. Rilmenidine (S 3341) and the sympathoadrenal system: adrenoreceptors, plasma and adrenal catecholamines in dogs
125. Central cardiovascular effects of phentolamine in chloralose‐anesthetized cats
126. Centrally acting sympathetic inhibitors.
127. Lack of pharmacokinetic interaction between moxonidine and hydrochlorothiazide
128. Medetomidine stereoisomers delineate two closely related subtypes of idazoxan (imidazoline) I‐receptors in the guinea pig
129. Effect of alpha‐adrenoceptor agonists on cell membrane potential in renal epitheloid Madin Darby canine kidney cells
130. The treatment of hypertensive patients with a calcium antagonist or moxonidine: A comparison